Search clinical trials for: PF-04965842

Total 1607 results

Pfizer

Completed

A Phase 1 Study To Evaluate Tolerability, Safety, And Pharmacokinetics Of Topical PF-06263276 In Healthy Subjects

Healthy

Belgium
Pfizer

Completed

Safety And Tolerability Study Of BID Titration Scheme With PF-05089771

Healthy

United States
Pfizer
Medivation, Inc.

Terminated

An Extension To The B1451027 Protocol To Evaluate The Long Term Safety And Tolerability Of Dimebon In Patients With Alzheimer's Disease

Alzheimer's Disease

Canada, United States, Puerto Rico
Pfizer

Completed

Multiple Oral Dose Safety, Tolerability And Pharmacokinetic Study Of PF-04287881 In Healthy Adult Subjects

Respiratory Tract Infections

United States
Biosense Webster, Inc.

Active, not recruiting

A Study For Treatment Of Paroxysmal Atrial Fibrillation (PAF) With The THERMOCOOL SMARTTOUCH SF Catheter and TRUPULSE Generator (SmartfIRE)

Atrial Fibrillation

Belgium, Denmark, Austria, Lithuania
Biogen

Completed

Study Of The PF-04958242 Blood Concentrations Of A Capsule Formulation Of PF-04958242 Compared To A Solution Formulation

Healthy

United States
Pfizer

Completed

A Study to Evaluate the Safety and Efficacy of PF-06650833, PF-06700841, and PF 06826647 in Adults With Hidradenitis Suppurativa

Acne Inversa

United States, Australia, Canada
Pain Therapeutics

Completed

Long-term Safety of PF-00345439 (Oxycodone)

Pain
Pfizer

Active, not recruiting

A Preliminary Study to Evaluate PF-07264660 in Healthy Participants

Healthy

United States
Laboratorios Sophia S.A de C.V.

Completed

Safety and Tolerability of the Preservative-free Ophthalmic Solution PRO-122 Compared With Krytantek Ofteno® (PRO-122/I)

Glaucoma

Mexico
Pfizer

Approved for marketing

Lorlatinib - PF-06463922
University of California, San Francisco
Population Services International

Completed

Improving Person-Centered Care for Family Planning in India (SPARQ_FPI)

Family Planning

India
Pfizer

Recruiting

A Study to Learn About the Safety and Effects of Rimegepant to Prevent Migraine in Chinese Subjects.

Migraine

China
University of Colorado, Denver
SpringWorks Therapeutics, Inc.

No longer available

Compassionate Use Protocol for PF-03084014 in Patients With Advanced Solid Tumor Malignancies

Neoplasm | Desmoid Tumor

United States
Conatus Pharmaceuticals Inc.
National Institute on Alcohol Abuse and Alcoholism (NIAAA)

Terminated

Study of IDN-6556 in Patients With Severe Alcoholic Hepatitis and Contraindications to Steroid Therapy (AH)

Alcoholic Hepatitis

United States
Pfizer

Completed

A Healthy Volunteer Trial to Gain Information About the Blood Concentrations of PF-06412562 After Oral Administration of a Modified Release Formulation in Fasted and Fed Conditions

Healthy

Belgium
Pfizer

Completed

A Study To Evaluate The Safety, Tolerability And Plasma Drug Levels Of PF-04447943 When Administered With Donepezil To Healthy Volunteer Subjects

Healthy

Singapore
Louisiana State University Health Sciences Center...
Parsemus Foundation

Completed

Use of a Live Attenuated Vaccine as an Immune-based Preventive Against COVID-19-associated Sepsis

Sepsis Syndrome

United States
University of California, San Francisco
National Parkinson Foundation

Completed

Mindfulness-based Cognitive Therapy (MBCT) for People With Parkinson's Disease

Depression | Parkinson Disease | Anxiety

United States
Norwegian School of Sport Sciences

Completed

The Effect of Strength Training and Protein Supplementation in Old Pre-frail Individuals

Aging

Norway
Centers for Disease Control and Prevention

Terminated

Efficacy of Artemisinin Combination Therapies for the Treatment of Uncomplicated P. Falciparum in Pregnancy in Brazil (PAACT-PF)

Malaria

Brazil
Maastricht University Medical Center
School for Midwifery Maastricht

Completed

Home or Home-like Hospital Birth

Pregnancy

Netherlands
Pfizer

Completed

Study In Healthy Adult Volunteers To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of PF-04427429

Healthy

Belgium
Pfizer

Completed

The Safety and Tolerability of PF-05089771 Will be Investigated in Healthy Subjects Over a 14 Day Dosing Period.

Pain

Belgium
Pfizer

Completed

A Study To Investigate The Clearance Of PF-04776548 From The Body Following A Very Low (Micro) Dose Of The Compound Using A Low Level Of Radiotracer To Help Quantify Expected Low Concentrations Of PF-04776548 In The Body

Human Immunodeficiency Virus (HIV)

United Kingdom
Pfizer

Completed

A Study To Evaluate Whether Food Affects The Plasma Drug Levels Of A 35 mg Single Dose Of PF-04447943 Taken Orally In Healthy Adult Participants

Healthy

United States
Pfizer

Completed

A Study to Evaluate Safety, Tolerability, Plasma Drug Levels, and Cognitive Response Following Multiple Doses of a Drug in Healthy Elderly Participants.

Healthy | Elderly

United States
Pfizer

Completed

A Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PF-04629991 in Healthy Volunteers

Healthy Volunteers

Belgium
Pfizer

Active, not recruiting

Long-term Safety and Efficacy Study and Dose-Escalation Substudy of PF 06838435 in Individuals With Hemophilia B

Hemophilia B

United States, Canada, Australia, Turkey
Pfizer

Completed

A Study To Investigate The Absorption, Distribution, Metabolism, And Excretion Of [14c]PF-06463922 In Healthy Male Volunteers

Healthy

United States
Pfizer

Completed

A Study To Understand How Radiolabelled PF-04449913 Is Taken Up By The Body, Broken Down And Then Removed From The Body

Healthy

United States
Pfizer

Completed

Multiple Dose Escalation Trial Of PF-04308515 In Healthy Volunteers

Healthy

United States
AIDS Malignancy Consortium
National Cancer Institute (NCI); The Emmes Company, LLC

Withdrawn

Gamma Secretase Inhibitor PF-03084014 in Treating Patients With AIDS-Associated Kaposi Sarcoma

HIV Infection | AIDS-related Kaposi Sarcoma | Recurrent Kaposi Sarcoma
Pfizer

Completed

First In Human Study Of Increasing Oral Doses Of PF-04634817

Healthy

United States
Pfizer

Completed

A Study To Assess The Safety Of PF-05335810 In Hypercholesterolemic Subjects

Hypercholesterolemia

United States
Pfizer

Completed

Bioavailability Study of PF-06651600 Formulations in Healthy Participants

Healthy Volunteers

Belgium
Pfizer

Completed

Study Of OX40 Agonist PF-04518600 Alone And In Combination With 4-1BB Agonist PF-05082566

Neoplasms

United States, Netherlands, France, Japan
Cairo University

Not yet recruiting

PRF Versus Advanced PRF in Sinus Augmentation

Maxillary Sinus
Pfizer

Recruiting

A Study to Learn About the Study Medicine (Maplirpacept) in People With Advanced Non-Hodgkin Lymphoma or Multiple Myeloma in China

Multiple Myeloma | Non-Hodgkin Lymphoma

China
Shire

Terminated

Efficacy and Safety Study of Ontamalimab as Induction Therapy in Participants With Moderate to Severe Crohn's Disease (CARMEN CD 305) (CARMEN CD 305)

Crohn's Disease

United States, Australia, Romania, Israel, Italy, Croatia, South Africa, Germany, Poland, United Kingdom, Austria, Japan, Lithuania, Netherlands, Russian Federation, Serbia
Pfizer

Terminated

Topical Multiple Ascending Dose Study for PF-06423264

Normal Healthy

Belgium
Memorial Sloan Kettering Cancer Center
Pfizer

Completed

Pfizer PF-06688992 in Patients With Stage III or Stage IV Melanoma

Melanoma

United States
Pfizer

Terminated

Study in Healthy Subjects to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PF-06687234

Healthy

Belgium
Pfizer

Terminated

Multiple Dose Study Of PF-05231023 In Obese Adult Subjects

Type 2 Diabetes Mellitus (T2DM)

United States
Pfizer

Withdrawn

A Study Of Oral PF-01913539 In Patients With Mild To Moderate Alzheimer's Disease

Dementia | Alzheimer's Disease | Dimebon | Investigational Drug
Wyeth is now a wholly owned subsidiary of Pfizer
Pfizer

Completed

Study Evaluating Multiple Doses Of GSI-953 Within The Elderly Population

Healthy

United States
Pfizer

Completed

Study of Multiple Oral Doses of PF-06835919 in Healthy Adult Japanese Participants

Healthy

Belgium
Pfizer

Terminated

A Phase 2 Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of PF-06252616 in Duchenne Muscular Dystrophy

Duchenne Muscular Dystrophy

United States, Australia, Canada, United Kingdom, Japan, Bulgaria, Italy, Poland
Pfizer

Completed

Single Dose of PF-06835919 Escalation Study in Healthy Adult Subjects

Non-alcoholic Fatty Liver Disease

United States
Pfizer

Completed

Safety and Pharmacokinetic Study of PF-06651600 in Japanese Healthy Volunteers

Healthy

Belgium

3

Subscribe